Brain Changes in Psoriasis After Secukinumab Treatment

Part of paid clinical trials in Miami, Florida.

Sponsor
University of Miami
Study ID
NCT04717466
Phase
PHASE4
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

Study Details

The purpose of this study is to assess the effect of a biologic drug targeting the Interleukin (IL)-17 pathway (secukinumab) on brain plasticity and examine whether the plastic changes correlate with the improvement of perception of well-being, itch, and pain in participants with psoriasis.

Key Dates

Start date
Jun 29, 2021
Status verified
Jun 2025
Primary completion
May 16, 2024
Completion
Mar 4, 2025

Study Design

Enrollment
20 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Psoriasis Group
    Psoriasis participants will be given Secukinumab for a total of 4 months. This is a 300mg subcutaneous injection that will occur at weeks 0, 1, 2, 3, 4, 8, and 12.
  • No Intervention: Healthy Group
    Healthy participants will not receive any intervention.

Primary Outcome Measure

Change in Gray Matter Density [ Time Frame: Baseline to Week 4 (Visit 3) ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of MiamiMiamiFlorida33136-

Related coverage on Hipa.ai

Find similar trials in Miami, FL

By condition
Psoriasis
By specialty
DermatologyRheumatologyAutoimmune disease
By research site
University of Miami· Miami, FL

Related Studies